Table 1.
Clinical characteristics of studied patients depending on the stage of chronic kidney disease (CAD—coronary artery disease; PAD—peripheral artery disease; TIA—transient ischaemic attack; eGFR—estimated glomerular filtration rate; BMI—body mass index; CHA2DS2-VASc—scoring system estimating a risk of stroke in patients with AF; EHRA—European Heart Rhythm Association).
| Variable | Group I eGFR ≥ 60 (n = 531) |
Group II eGFR 45–59 (n = 149) |
Group III eGFR < 45 (n = 97) |
Statistical Analysis (p) |
|||
|---|---|---|---|---|---|---|---|
| n (%) | n (%) | n (%) | I–III | I vs. II | I vs. III | II vs. III | |
| Male sex | 282 (53.7) | 58 (39.5) | 23 (23.7) | <0.001 | <0.001 | <0.001 | 0.013 |
| Age > 65 (years) | 278 (52.3) | 123 (82.5) | 80 (82.5) | <0.001 | <0.001 | <0.001 | 0.988 |
| Age > 75 (years) | 90 (16.9) | 57 (38.3) | 51 (52.6) | <0.001 | <0.001 | <0.001 | 0.027 |
| Hypertension | 397 (74.8) | 124 (83.8) | 89 (91.7) | <0.001 | 0.022 | <0.001 | 0.070 |
| Diabetes | 109 (20.6) | 31 (20.9) | 33 (34.4) | 0.010 | 0.920 | 0.003 | 0.020 |
| CAD/PAD | 143 (26.9) | 52 (35.1) | 41 (42.3) | 0.004 | 0.051 | 0.002 | 0.261 |
| History of stroke/TIA | 34 (6.4) | 10 (6.8) | 18 (18.6) | <0.001 | 0.877 | <0.001 | 0.005 |
| Oral anticoagulants | 357 (69.0) | 109 (75.2) | 77 (85.6) | 0.004 | 0.154 | <0.001 | 0.057 |
| Beta-blocker use | 184 (34.9) | 57 (38.3) | 30 (31.2) | 0.526 | 0.452 | 0.487 | 0.263 |
| Amiodarone | 173 (32.6) | 39 (26.2) | 31 (32.0) | 0.325 | 0.136 | 0.904 | 0.326 |
| Propafenone | 42 (7.9) | 9 (6.0) | 8 (8.2) | 0.724 | 0.444 | 0.910 | 0.505 |
| Antazoline | 172 (32.4) | 53 (35.6) | 20 (20.6) | 0.036 | 0.466 | 0.021 | 0.012 |
| Overlap | 144 (27.1) | 48 (32.2) | 38 (39.2) | 0.042 | 0.222 | 0.016 | 0.263 |
| Successful PCV | 368 (69.3) | 92 (61.7) | 59 (60.8) | 0.092 | 0.081 | 0.100 | 0.885 |
| Safety endpoint | 9 (1.7) | 2 (1.34) | 6 (6.2) | 0.015 | 0.763 | 0.008 | 0.036 |
| Death | 0 (0.0) | 0 (0.0) | 0 (0.0) | - | - | - | - |
| Bradycardia < 45 bpm | 6 (1.13) | 1 (0.7) | 4 (4.1) | 0.050 | 0.624 | 0.030 | 0.061 |
| Syncope | 1 (0.19) | 0 (0.0) | 0 (0.0) | 0.793 | 0.596 | 0.669 | - |
| Hypotension | 2 (0.4) | 1 (0.7) | 1 (1.0) | 0.680 | 0.633 | 0.391 | 0.759 |
| Variable | Group I | Group II | Group III | Statistical Analysis (p) | |||
| Mean ± SD | Mean ± SD | Mean ± SD | I–III | I vs. II | I vs. III | II vs. III | |
| Age (years) | 64.3 ± 12.2 | 71.0 ± 9.7 | 74.0 ± 10.5 | <0.001 | <0.001 | <0.001 | 0.013 |
| eGFR (mL/min) | 80.7 ± 12.3 | 53.6 ± 4.2 | 36.9 ± 7.1 | <0.001 | <0.001 | <0.001 | <0.001 |
| BMI | 27.8 ± 4.4 | 28.7 ± 3.9 | 28.5 ± 5.3 | 0.477 | 0.212 | 0.776 | 0.814 |
| CHA2DS2VASc | 2.7 ± 1.6 | 3.6 ± 1.6 | 4.4 ± 1.4 | <0.001 | <0.001 | <0.001 | <0.001 |
| EHRA score | 2.5 ± 0.7 | 2.6 ± 0.8 | 2.2 ± 0.9 | 0.005 | 0.043 | 0.021 | 0.003 |
| Drug (total dose): | |||||||
| Amiodarone (mg) | 509.0 ± 258.2 | 489.2 ± 257.6 | 422.4 ± 251.5 | 0.045 | 0.494 | 0.014 | 0.110 |
| Propafenone (mg) | 265.0 ± 210.9 | 288.1 ± 247.1 | 289.4 ± 227.6 | 0.937 | 0.726 | 0.909 | 0.823 |
| Antazoline (mg) | 214.3 ± 78.8 | 231.0 ± 81.3 | 209.4 ± 71.4 | 0.283 | 0.167 | 0.653 | 0.151 |